Goldman Sachs analysts now paying attention to Salix again
September 17, 2013 at 11:03 AM EDT
Goldman Sachs announced it will resume coverage of Raleigh-based Salix Pharmaceuticals and gave it an initial grade of “neutral” with a price target of $73...